News
At Cell-Easy, we provide end-to-end GMP manufacturing services for advanced therapy medicinal products (ATMPs), with a strong focus on compliance, scalability, and reliability.
We help biotech and pharma companies bring innovative cell therapies from the lab to the clinic by combining high-quality starting material sourcing, robust process development, and clinical-grade GMP production that meets international standards (MHRA, ANSM, EMA, FDA readiness).
Whether you need early clinical batches or large-scale production, our tailored solutions optimize your process, minimize risks, and accelerate time-to-clinic.
Cell-Easy Signs Groundbreaking Manufacturing Contract, Paving the Way for Local Hospitals to Offer Next-Generation CAR-T Therapy
Learn more: Cell-Easy Signs Groundbreaking Manufacturing Contract, Paving the Way for Local Hospitals to Offer Next-Generation CAR-T TherapyCell-Easy Signs Groundbreaking Manufacturing Contract, Paving the Way for Local Hospitals to Offer Next-Generation CAR-T Therapy This agreement with a pioneer European C&G company will soon enable the initiation of new clinical trials in South of France based on innovative CAR-T cell treatments The French Contract Development and Manufacturing Organization (CDMO) Cell-Easy stands out and…
Accelerating Patient Access to Advanced Cell-based Therapies through the Signature of a Service Agreement between the French CDMO and the Toulouse University Hospital (CHU Toulouse)
Learn more: Accelerating Patient Access to Advanced Cell-based Therapies through the Signature of a Service Agreement between the French CDMO and the Toulouse University Hospital (CHU Toulouse)Accelerating Patient Access to Advanced Cell-based Therapies through the Signature of a Service Agreement between the French CDMO and the Toulouse University Hospital (CHU Toulouse) Accelerating Patient Access to Advanced Cell-based Therapies through the Signature of a Service Agreement between the French CDMO and the Toulouse University Hospital (CHU Toulouse) This agreement between the two…
IMPD Approval for FIH Trial in Systemic Sclerosis – Cell Easy
Learn more: IMPD Approval for FIH Trial in Systemic Sclerosis – Cell EasyIMPD Approval for FIH Trial in Systemic Sclerosis – Cell Easy EU regulatory approval to administer Adipose-derived mesenchymal Stem Cells (ASCs) in patients with ischemic digital ulcers marks key milestone for partners Cell-Easy, a French Contract Development and Manufacturing Organization (CDMO) focused on advanced cell therapies, and the Toulouse University Hospital, today announce that they…
Cell-Easy is pleased to welcome Mrs. Gisele Deblandre, formerly CSO at MaSTherCell, as Chief Scientific Officer
Learn more: Cell-Easy is pleased to welcome Mrs. Gisele Deblandre, formerly CSO at MaSTherCell, as Chief Scientific OfficerCell-Easy is pleased to welcome Mrs. Gisele Deblandre, formerly CSO at MaSTherCell, as Chief Scientific Officer Cell-Easy, a specialized contract development and manufacturing organization (CDMO) in cell therapy, proudly announces the appointment of Mrs. Gisele Deblandre as the Chief Scientific Officer. Over the years, Cell-Easy has recognized the challenges faced by biotechs in bridging the…
IUCT-Oncopole and Cell-Easy sign a MOU to accelerate cancer patient access to advanced cell-based therapy
Learn more: IUCT-Oncopole and Cell-Easy sign a MOU to accelerate cancer patient access to advanced cell-based therapyIUCT-Oncopole and Cell-Easy sign a MOU to accelerate cancer patient access to advanced cell-based therapy IUCT-Oncopole – Nouvelle fenêtre and Cell-Easy announced today the signing of a Memorandum of Understanding to enhance their strategic collaborative relationship and open access to advanced cell-based therapies. This partnership aims to drive innovation in public health and improve access to promising new cancer…
Cell-Easy Appoints CDMO Expert Dr. Ribault to Its Board
Learn more: Cell-Easy Appoints CDMO Expert Dr. Ribault to Its BoardCell-Easy Appoints CDMO Expert Dr. Ribault to Its Board Cell-Easy is a leading contract development and manufacturing organization (CDMO) with a strong foothold in Good Manufacturing Practice (GMP) manufacturing services for immune cells (T, NK cells) and adult stem cells (MSCs, iPSCs). Since 2020, the company keeps expanding into genetically modified cells such as CAR-T…